How Common Is MRSA: US and Global Prevalence Rates

MRSA accounts for a substantial share of all Staphylococcus aureus infections worldwide, but exactly how common it is depends heavily on where you look and which population you examine. In the United States, hospital-onset MRSA bloodstream infections dropped roughly 74% between 2005 and 2016, yet community-onset cases fell more slowly, and the decline has stalled in recent years. Globally, the picture is even more uneven: some northern European countries report MRSA in fewer than 1% of staph isolates, while parts of Africa and Latin America see rates above 40%. The numbers shift further when you look beyond hospitals to nursing homes, neonatal units, prisons, and pig farms.

MRSA Trends in US Hospitals and Communities

The most comprehensive US surveillance data come from the CDC’s Emerging Infections Program, which tracks MRSA bloodstream infections across multiple states. Between 2005 and 2016, hospital-onset MRSA bloodstream infections fell by about 74%, while community-onset cases declined by roughly 40%.¹ That sounds like good news, and it is, but the fine print matters. The steep drop in hospital-onset cases happened mostly before 2012, when rates were falling by about 17% per year. After 2013, the decline essentially plateaued. And in the community, the infections most clearly tied to healthcare contact (people recently discharged, dialysis patients, those with indwelling devices) drove most of the improvement, while truly community-associated bloodstream infections barely budged, declining only about 2.5% per year.¹

Community-acquired MRSA (often called CA-MRSA) became a major concern in the early 2000s, when outbreaks appeared among people with no obvious hospital exposure. A meta-analysis modeling the epidemic curves in several US populations found that peak incidence varied wildly by group, from about 84 per 100,000 in the military Tricare system to roughly 566 per 100,000 among Maryland veterans. By around 2011, those curves appeared to be leveling off, suggesting the explosive growth phase of community-acquired MRSA had passed.² The plateau, though, is not the same as disappearance. CA-MRSA remains a leading cause of skin and soft tissue infections in emergency departments across the country.

The Global Patchwork

MRSA prevalence worldwide is anything but uniform. The best way to understand global rates is region by region, because local antibiotic use patterns, infection-control infrastructure, and dominant bacterial strains all shape the numbers.

Europe

European surveillance has long shown a dramatic north-to-south gradient. Across the continent between 1999 and 2002, MRSA prevalence among staph isolates varied almost 100-fold, from under 1% in Scandinavian countries to over 40% in parts of southern and western Europe.³ That gap has narrowed somewhat since then, largely because countries with high rates (the UK, France, and others) invested heavily in infection control and antibiotic stewardship. Scotland, for example, achieved roughly a 50% reduction in hospital MRSA density through combined antibiotic stewardship and infection prevention measures.⁴ But the gradient persists: Nordic countries still report much lower MRSA percentages than Mediterranean ones.

Asia-Pacific

The Asia-Pacific region spans some of the widest extremes on Earth. A systematic review of 19 locations found MRSA infection prevalence ranging from 0% to 73% between 2000 and 2016.⁵ In community-level studies, the general public’s MRSA carriage prevalence ran from essentially zero to over 23%, with India reporting the highest figures (around 16.5% to 23.5%), followed by Vietnam and Taiwan.⁶ Much of this variation traces to differences in antibiotic availability. In countries where antibiotics can be purchased over the counter with minimal regulation, selection pressure for resistance is intense.

Latin America

MRSA is already the leading cause of hospital-acquired staph infections across much of Latin America, and community-acquired cases are climbing.⁷ A large prospective study across nine Latin American countries found that MRSA accounted for 45% of all S. aureus bloodstream isolates.⁸ Genetic analysis of those isolates revealed regional differences in which MRSA strains dominate. In most countries, a lineage called CC5 was most common, but in Colombia and Ecuador, a variant of the notorious USA300 strain accounted for over 72% of MRSA bloodstream isolates.⁸

Africa and the Middle East

Surveillance data from Africa and the Middle East are thinner, but what exists is concerning. A recent systematic review and meta-analysis of mostly hospital-based studies across Africa found a pooled MRSA proportion of about 42%, with northern Africa significantly higher at roughly 56% compared to about 37% in sub-Saharan Africa.⁹ In East Africa, one study found MRSA in over half of staph isolates tested.¹⁰ In the Middle East and North Africa, nasal colonization rates ranged widely depending on sub-region, from under 1% to 16%, while the proportion of MRSA among clinical staph infections ranged from 9% in some Gulf states to 67% in parts of the Levant.¹¹

Carrying MRSA Without Knowing It

A person can harbor MRSA in their nose or on their skin for weeks or months without ever developing an infection. This silent carriage matters because carriers can spread the bacteria to others and are at elevated risk of future infections themselves. In the general population of most high-income countries, nasal MRSA carriage runs somewhere below 1% to 2%. An Australian community survey, for instance, found MRSA in the noses of fewer than 1% of adults.¹² But carriage rates climb sharply in populations with frequent healthcare exposure. Among healthcare workers in long-term care facilities, one study found MRSA colonization running at about 12%, significantly higher than in emergency medical technicians with less patient contact.¹³

Settings Where MRSA Concentrates

MRSA is not randomly distributed. It clusters in environments where people live in close quarters, share surfaces, and have compromised health or broken skin. Three settings stand out for their unusually high burden.

Nursing Homes and Long-Term Care

Nursing homes are among the most stubbornly affected settings. In one large US study of 626 nursing homes, 82% had at least one resident with an invasive MRSA infection, and a fifth of those facilities accounted for half of all cases.¹⁴ The facilities with the worst rates tended to have more male residents, more patients with feeding tubes, and higher rates of MRSA in the surrounding community hospitals.¹⁴ Colonization surveys paint a similar picture: a Taiwanese longitudinal study found cumulative MRSA colonization reaching about 40% of residents over six months.¹⁵ In Germany, a cross-sectional study across multiple nursing homes found an average MRSA prevalence of about 5%, though individual facilities ranged from 0% to nearly 27%.¹⁶

Prisons and Jails

Correctional settings have seen MRSA outbreaks in multiple US states, and infection rates in jails and prisons consistently exceed those in the surrounding communities.¹⁷ A systematic review of MRSA in incarcerated populations identified risk factors including sharing soap or personal items, communal laundering, infrequent handwashing, younger age, and prior skin infections.¹⁸ The combination of overcrowding, limited hygiene infrastructure, and frequent skin-to-skin contact creates near-ideal conditions for staph transmission.

Neonatal and Pediatric Intensive Care

Newborns in intensive care units face a particular vulnerability. A meta-analysis found that roughly 1.9% of babies admitted to neonatal or pediatric ICUs already carried MRSA, and about 4% to 6% picked it up during their stay.¹⁹ The gap between inborn and outborn neonates was striking: babies transferred from other facilities were colonized at about 5.8%, compared to just 0.2% of babies born at the admitting hospital.¹⁹ A more recent systematic review focusing solely on neonatal ICUs reported a cumulative incidence of about 7.2% across over 100,000 participants, with hospital-acquired MRSA incidence at roughly 11% compared to about 2.7% for community-acquired strains.²⁰ Colonized neonates face dramatically higher odds of developing an actual MRSA infection during hospitalization.

Why MRSA Kills More Than Ordinary Staph

Methicillin resistance does not just make treatment harder; it makes outcomes worse. A pooled analysis of multiple meta-analyses confirmed that patients with MRSA bloodstream infections face roughly double the risk of dying compared to those infected with methicillin-susceptible S. aureus.²¹ In critically ill patients, the mortality gap can be even wider: one study of ICU patients found 30-day mortality of about 53% for MRSA bloodstream infections compared to about 18% for susceptible staph.²² Part of this higher mortality is simply that MRSA infections force clinicians onto second-line antibiotics that are slower to work, harder to dose, and carry more side effects. Part of it is confounding: the patients who get MRSA tend to be sicker and more debilitated to begin with. But even after adjusting for those differences, methicillin resistance itself remained an independent predictor of death in multivariate analyses.²²

Socioeconomic Disparities in MRSA Rates

In the US, Black Americans have been consistently found to have higher rates of community-associated MRSA than white Americans, with one surveillance study reporting an incidence of about 7.6 per 100,000 among Black individuals compared to about 4.6 per 100,000 among white individuals.²³ But this disparity turns out to be almost entirely explained by socioeconomic factors. When researchers accounted for neighborhood-level measures of poverty, education, income, housing value, and healthcare access, 91% of the racial gap disappeared, and the remaining difference was no longer statistically significant.²³ The practical implication is clear: MRSA concentrates where poverty concentrates. Neighborhood poverty was associated with dramatically higher rates of invasive MRSA, while living in high-value housing areas was associated with lower rates. Extreme income inequality within a neighborhood was an independent risk factor as well.²⁴

What MRSA Infections Cost

The economic burden is substantial. Among elderly hospitalized patients in the US, the attributable cost of a hospital-onset invasive MRSA infection was estimated at roughly $22,000 per case.²⁵ For community-acquired MRSA, the per-case cost runs from a few thousand dollars to the insurer up to roughly $20,000 in total societal costs depending on patient age, when productivity losses from missed work and long-term disability are included. At a population level, CA-MRSA was estimated to impose an annual burden of $478 million to $2.2 billion on insurers and $1.4 billion to $13.8 billion on society in the US alone.²⁶ Those wide ranges reflect uncertainty about exactly how many CA-MRSA infections occur (many skin abscesses never get cultured and reported) and how to value lost productivity. Either way, the cost is measured in billions.

MRSA on Surfaces and in Households

One reason MRSA persists in communities is that the bacteria survive on everyday surfaces for days to weeks. In a study of 50 households with children who had been diagnosed with MRSA infections, the bacteria were recovered from surfaces in nearly half the homes. Bed linens, TV remote controls, and bathroom hand towels were the most frequently contaminated items.²⁷ In about 40% of those homes, at least one surface carried the same MRSA strain that had infected the child, suggesting the environment was actively contributing to reinfection or transmission to family members.²⁷ Hospital environments tell a similar story: bed side rails and overbed tables in rooms of MRSA-positive patients are frequently contaminated.²⁸ In nursing homes, shared rooms were identified as a risk factor for MRSA transmission between patients, likely because of the constant opportunity to contact contaminated surfaces.²⁹

The USA300 Strain and Why Lineages Matter

Not all MRSA is one bug. The bacteria come in genetically distinct lineages, and some are far more successful at spreading than others. In the US, the strain known as USA300 went from causing a handful of unusual community infections in the late 1990s to becoming the dominant cause of MRSA skin and soft tissue infections within a decade.³⁰ In one long-term care facility, USA300 climbed from about 11% of all MRSA isolates in 2002 to 64% by 2006.³¹ USA300 carries a toxin called Panton-Valentine leukocidin (PVL) that can destroy white blood cells and is associated with severe skin abscesses and, less commonly, necrotizing pneumonia.

Genomic analysis suggests USA300 originated in North America and then spread internationally. A Latin American variant, called USA300-LV, has become the dominant MRSA strain in Colombia and Ecuador, where it accounted for at least 72% of MRSA bloodstream isolates in a multicenter study.⁸ Whole-genome sequencing has become increasingly viable for tracking how these lineages move between hospitals, communities, and countries, giving public health officials a resolution that older typing methods could not achieve.³²

Livestock-Associated MRSA

Since the mid-2000s, a distinct branch of MRSA has been found living in pigs, cattle, and poultry. In Europe and North America, livestock-associated MRSA predominantly belongs to a lineage called CC398, and it readily colonizes people who work closely with animals.³³ A study of pig farms in southern Italy found MRSA colonization in about 22% of farm workers, and over 94% of those human isolates matched the MRSA strains found in the pigs on the same farm, pointing to direct animal-to-human transmission.³⁴ Some of those workers were still carrying MRSA a full year later. The good news, at least so far, is that livestock-associated MRSA has shown limited ability to spread deeply into the general population. A Norwegian investigation of three outbreak clusters involving 26 pig farms found that all MRSA CC398 isolated from humans without direct links to the outbreaks were genetically distinct from the outbreak strains, suggesting the bacteria were not cascading far beyond the farming community.³⁵ Whether that remains true as intensive farming expands in lower-income countries is an open question researchers are watching carefully.

What Has Actually Worked to Reduce MRSA

The reductions seen in US and European hospitals since the mid-2000s did not happen by accident. They came from a combination of interventions: hand hygiene programs, admission and discharge screening for MRSA carriage, environmental cleaning upgrades, and changes in antibiotic prescribing. In a study at two UK hospitals, introducing alcohol-based hand gel alone was associated with a 21% to 30% absolute drop in the proportion of staph isolates that were MRSA. Adding chlorine-based environmental disinfection and admission screening drove further reductions.³⁶ That same study found that increased use of macrolide and quinolone antibiotics was associated with rising MRSA rates, reinforcing the link between antibiotic prescribing habits and resistance patterns.³⁶

Scotland’s national experience provides a larger-scale example. Antibiotic stewardship alone was associated with a 54% reduction in hospital MRSA density and a 37% reduction in the community. When combined with infection prevention and control measures, the reductions reached about 50% in hospitals and 47% in the community.⁴ The lesson from these efforts is that MRSA is not an unstoppable force. Where healthcare systems invest seriously in basic infection control and rein in unnecessary antibiotic use, rates come down. Where those efforts stall or never begin, as in many lower-income settings with limited surveillance and over-the-counter antibiotic access, MRSA continues to thrive.